AIX and BGM Group Forge Strategic Partnership to Revolutionize AI-Driven Healthcare and Insurance

AIX and BGM Group Forge Strategic Deal, Leading Healthcare, Pharma, and Insurance Industry Expansion with AI - AIX (NASDAQ:AIFU), BGM Group (NASDAQ:BGM)

GUANGZHOU, China, Nov. 29, 2024 (GLOBE NEWSWIRE) -- AIX Inc. AIFU (the "Company" or "AIX"), a leading independent technology-driven financial services provider in China, today announced that it has entered into a strategic transaction agreement (the "Agreement") with BGM Group Ltd. BGM ("BGM"), a leading global provider of premium pharmaceutical products and services. Pursuant to the Agreement, AIX agreed to transfer the equity interests of its intelligent platform consisting of RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"), valued at approximately US$140.0 million, to BGM in exchange for 69,995,661 of BGM's Class A ordinary shares, at a consideration valuation of US$2.00 per share. The transaction is expected to close by the end of 2024, subject to certain closing conditions. Upon completion of the transaction, AIX will hold approximately 72.0% of BGM's equity interests and approximately 3.4% of its voting power while BGM will gain full control of RONS Technology and Xinbao Investment. The Company anticipates that RONS Technology and Xinbao Investment will both gain broader development opportunities through this transaction. BGM's extensive resources in the healthcare sector will create more application scenarios for both parties' products and services, further unlocking their growth potential. AIX, through its shareholding in BGM, will indirectly participate in the value creation of RONS Technology and Xinbao Investment, ensuring that its shareholders can continue to benefit from their future value growth. Additionally, this transaction will accelerate AIX's strategic expansion into the pharmaceutical and healthcare sector. This will enable the Company to fully capitalize on the opportunities brought by the aging population and the silver economy in China, injecting new momentum into the company's future growth. Mr. Yinan Hu, Chief Executive Officer of AIX, commented: "AI-driven innovation is the future of the insurance industry. Our platform has already shown tremendous potential within the insurance sector, but achieving broader growth requires a more open perspective and stronger ecosystem support. We believe this partnership with BGM will allow our intelligent platform to reach a broader user base and unleashes the potential of AI technologies beyond insurance. "This collaboration represents an important milestone in our strategic transformation. BGM, as a leading global player in the pharmaceutical industry, brings deep expertise, an international perspective, and a solid industry position, all of which will help fuel the development of our intelligent platform in the pharmaceutical and healthcare sectors. With this partnership, we will be able to expand our intelligent capabilities from insurance to the pharmaceutical and healthcare industries to seize opportunities in the silver economy, and foster higher-quality development. "We will continue to be a key user of the intelligent platform and actively invest resources to unlock its technological potential. We firmly believe that this partnership will unlock immense opportunities for both AIX and our intelligent platform while delivering greater long-term value to our clients, partners and shareholders." Mr. Chen Xin, Chief Executive Officer of BGM, stated, "We are deeply impressed by AIX's achievements in digitalization and intelligent transformation. Their expertise and technological advancements offer valuable insights for advancing our intelligent transformation in the healthcare and pharmaceutical sectors. We believe that this partnership will not only strengthen our technological competitiveness but also accelerate our strategic positioning, enabling us to provide more efficient and intelligent solutions to the global market. I look forward to a mutually beneficial collaboration that will shape the future of both parties." BGM operates through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. and its affiliates. Since its inception in 1969, BGM has evolved into a leading provider of premium products and services within the global pharmaceutical industry, skillfully harnessing over 50 years of cutting-edge biotechnological production expertise in bio-fermentation, bio-extraction, and pharmaceutical formulation. BGM has established a strong position in the international pharmaceutical industry through extensive pharmaceutical experience, innovative technique, and expansion into global markets. Founded in 2009, RONS Technology, a wholly-owned subsidiary of AIX, specializes in developing digital and intelligent technologies for the financial and insurance industries. RONS Technology boasts extensive experience in insurtech, having introduced disruptive innovations through its RONS Open Platform and flagship product Du Xiaobao. RONS Technology has steadily built a strong presence within the insurtech landscape, offering substantial growth potential and development opportunities. Established in 2004, Xinbao Investment, an affiliate under AIX's control, has developed a professional integrated online and offline insurance trading and service platform known as "Baowang". Baowang provides comprehensive risk protection solutions for individuals, families, and small to medium-sized enterprises through the integration of technology, products, and services. The platform currently offers over 300 flagship products from more than 30 insurance companies, addressing various protection needs such as critical illness, term life, accident, health, travel, and corporate insurance. About AIX Inc. AIX, established in 1998, is a leading intelligent technology-driven independent financial services provider in China. It provides 400 million middle-class families with insurance protection, wealth management, and value-added services and provides independent financial advisors and various insurance/financial sales organizations with technical support and comprehensive solutions. Through AI-driven insights and cutting-edge digital tools, AIX has successfully established itself as a leader in intelligent transformation within the financial services industry. Forward-looking Statements This press release contains statements of a forward-looking nature. These statements, including the statements relating to the Company's future financial and operating results, are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will", "expects", "believes", "anticipates", "intends", "estimates" and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about AIX Inc. and the industry. Potential risks and uncertainties include, but are not limited to, those relating to its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the evolving regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, quarterly variations in its operating results caused by factors beyond its control including macroeconomic conditions in China. Except as otherwise indicated, all information provided in this press release speaks as of the date hereof, and AIX Inc. undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although AIX Inc. believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by AIX Inc. is included in AIX Inc.'s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. For more information, please contact: AIX Inc. Investor Relations Tel: +86 (20) 8388-3191 Email: ir@aifugroup.com Market News and Data brought to you by Benzinga APIs

AIX Inc. (NASDAQ:AIFU): Reshaping AI Insurance and the Healthcare Industry--A Promising Future Ahead? - AIX (NASDAQ:AIFU), BGM Group (NASDAQ:BGM)

HONG KONG, Nov. 29, 2024 /PRNewswire/ -- AIX Inc. AIFU is a leading company focused on insurance agency and claims services. Recently, the company has been gradually pushing for an intelligent and diversified transformation, aiming to capture growth opportunities in the AI insurance and healthcare sectors. The restructuring of its high-quality assets and a strategic partnership with BGM Group Ltd. BGM are expected to create a second growth curve for the company's future performance. 1. Restructuring Quality Assets to Build a Smarter Future AIFU has recently undertaken the restructuring of its core assets, involving an amount of $140 million, including RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"). This is not a simple "sale" transaction; the restructuring involves the Duxiaobao AI insurance platform, which provides intelligent solutions to the insurance market through AI and big data. AIFU exchanged these assets for 72% of BGM Group's shares, becoming the majority shareholder of BGM Group. This transaction is expected to significantly increase BGM Group's market value and open up new opportunities for AIX Inc.'s future development. Key Points of Asset Restructuring: Business Growth Potential: The Duxiaobao AI insurance platform has strong technical barriers (based on Baidu's big data platform) and market potential (AIFU's insurance brokerage platform) and is expected to drive significant performance growth for BGM Group in the coming years. AIFU retains control of the future development of Duxiaobao through its stake in BGM.Undervaluation: BGM Group currently has a market value of only $52 million, yet its new business has a market potential that far exceeds its current valuation. As the majority shareholder of BGM, AIFU stands to benefit from BGM's business growth.Dual Business Synergy: BGM Group is a global leader in the pharmaceutical industry. Through deep cooperation with BGM Group, AIFU has strengthened its presence in both the AI insurance and healthcare sectors, with the potential to become a leader in these two industries. 2. BGM Group: From a Market Value of Millions to a Potential Leader in AI Insurance Technical Advantage: BGM is positioned to take a leading role in the AI + insurance market transformation by leveraging the Duxiaobao AI insurance platform and Baidu's big data capabilities. It can offer personalized insurance solutions to the market.Market Opportunity: The global AI insurance industry is on the brink of a major expansion, and BGM is well-positioned to seize this opportunity.Industry Trend: The "pharmaceutical + insurance" model is gaining momentum in China, where over 400 million people have chronic conditions. Annual medical expenses account for 60% of total expenses, yet related premiums constitute only 5% of health insurance, revealing a significant protection gap. From 2012 to 2022, China's commercial health insurance experienced a compound annual growth rate (CAGR) of 25.93%, far surpassing the average growth rate of the insurance industry, indicating tremendous growth potential. Successful cases such as CVS's acquisition of Aetna and UnitedHealth Group's integration with OptumRx validate the critical value of "pharma + insurance" collaborations in optimizing costs, innovating supply chains, and facilitating data sharing. Currently, BGM Group's market value has not yet been fully realized in the secondary market. If the AI insurance business expands rapidly, BGM Group's market value and stock price are likely to undergo significant revaluation. 3. AIFU's Undervaluation As of December 31, 2023, AIFU's total revenue reached $3.198 billion, reflecting a year-on-year increase of 14.98%, and net profit was $289 million, demonstrating a year-on-year increase of 237.25%. As the largest insurance brokerage platform in China, AIFU has a Price-to-Earnings (P/E) ratio of only 3.5x. In comparison, Prudential Insurance reported revenue of $11.9 billion, up 143%, with a net profit of $1.712 billion, up 271.72%. Meanwhile, Prudential Financial's revenue was $53.979 billion, down 5.1%, but its net profit rose by 249%, reaching $2.508 billion. These results highlight AIFU's significant growth potential. With a market value of approximately $76 million, AIFU stands in stark contrast to Prudential Insurance (PUK, market value of $21.7 billion) and Prudential Financial (PRU, market value of $46.1 billion). While Prudential focuses primarily on traditional insurance products, AIFU is poised to disrupt the industry with AI-driven solutions, supported by Baidu's big data, which will effectively reduce costs, expand market share, and improve customer satisfaction. 4. Pharmaceutical and Healthcare Strategy Driving Valuation Growth AIFU not only focuses on the AI insurance business but also heavily invests in the pharmaceutical and healthcare sectors, seizing new opportunities brought about by global population aging. Key driving factors include: Aging Population: An increase in the elderly population leads to a greater demand for insurance and healthcare services.AI + Health Management: AIFU plans to use AI technology to offer customized insurance products and services for its client base. Through the strategic restructuring with BGM Group, AIFU has formed a powerful alliance in both the AI insurance and healthcare sectors, positioning itself to become an industry leader. Whether in terms of BGM Group's valuation potential or AIFU's business expansion, this transaction presents a unique opportunity for investors. The dual drivers of AI insurance and healthcare will be the cornerstone of the company's future development. View original content:https://www.prnewswire.com/news-releases/aix-inc-nasdaqaifu-reshaping-ai-insurance-and-the-healthcare-industrya-promising-future-ahead-302318841.html SOURCE AIX Inc. Market News and Data brought to you by Benzinga APIs

BGM Group Ltd. Pioneers Innovation in AI and Intel Technology, Fostering Holistic Integration of Healthcare and Insurtech - AIX (NASDAQ:AIFU), BGM Group (NASDAQ:BGM)

CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. BGM ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. AIFU ("AIX") valued at 1 billion RMB (approximately $140 million). The intelligent platform encompasses AIX's subsidiaries - RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"). Completion of the transaction is anticipated by the end of 2024. Through this strategic acquisition, BGM formally ventures into the domains of AI intelligent technology and financial and insurance services, setting the stage for diversified growth beyond biopharmaceuticals and inaugurating a new era for the Company in the digital and intelligent landscape. Mr. Xin Chen, CEO of BGM, commented, "AIX's efforts in digital innovation and intelligent transformation have yielded remarkable outcomes. Their accumulated technology and expertise will serve as a crucial reference for our own transformation in the pharmaceutical and healthcare sectors. This collaboration will not only bolster BGM's technological capabilities but also expedite our strategic development, enabling us to deliver more efficient and intelligent solutions to the global market. This partnership represents a mutually beneficial opportunity and I am optimistic about our future together." Mr. Hu Yinan, CEO of AIX, stated, "Intelligent technology is the future of the insurance sector. AIX's intelligent platform has already exhibited significant potential within the industry. However, broader advancement requires an open industry perspective and ecological support. Partnering with BGM will allow our platform to reach a wider user base and unlock greater potential for AI technology beyond the insurance realm. Furthermore, this collaboration aligns with national elderly care policies and promotes the growth of the silver economy. By extending our intelligent capabilities from insurance into the pharmaceutical and healthcare sectors, we aim to facilitate industry transformation through technology and propel AIX's growth. AIX will maintain its role as the primary user of the intelligent platform, actively investing resources to maximize its technological capabilities. We are confident that this collaboration will create new opportunities for both AIX and the intelligent platform, enhancing value for our customers, industry partners, and shareholders." Founded in 2009, RONS Technology, a wholly-owned subsidiary of AIX, specializes in developing digital and intelligent technologies for the financial and insurance industries. RONS Technology boasts extensive experience in insurtech, having introduced disruptive innovations through its RONS Open Platform and flagship product Du Xiaobao. RONS Technology has steadily built a strong presence within the insurtech landscape, offering substantial growth potential and development opportunities. Established in 2004, Xinbao Investment has developed a professional integrated online and offline insurance trading and service platform known as "Baowang". Baowang provides comprehensive risk protection solutions for individuals, families, and small to medium-sized enterprises through the integration of technology, products, and services. The platform currently offers over 300 flagship products from more than 30 insurance companies, addressing various protection needs such as critical illness, term life, accident, health, travel, and corporate insurance. By acquiring RONS Technology and Xinbao Investment, BGM will effectively integrate resources from intelligent technology and biopharmaceuticals, creating a new landscape for the synchronized development of "healthcare, medicine, and insurance" in the global market. The technological innovations from RONS Technology, particularly the pioneering achievements of Du Xiaobao in insurance sales, will empower BGM to strengthen its competitive advantage at the intersection of medical technology and insurance technology, offering users comprehensive and intelligent healthcare and insurance solutions while further expanding its global influence. Moreover, RONS Technology and Xinbao Investment will benefit from enhanced development opportunities arising from this transaction. BGM's robust presence in the healthcare sector, especially its extensive footprint in the global pharmaceutical market, will provide additional application scenarios for the products and services of both entities. RONS Technology and Xinbao Investment intend to leverage BGM's international market network and pharmaceutical expertise to explore novel development models within the healthcare and insurance industries, continuously broaden their market reach, and serve as potent profit generators for BGM in the future. About BGM Group Ltd BGM Group Ltd,headquartered in Chengdu, China, is an innovative company dedicated to the fields of biopharmaceuticals, bio-extraction, and medical health. Our current product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. The oxytetracycline API not only provides raw materials for pharmaceutical companies to produce human antibiotics but also supports the global breeding and livestock industries to ensure the safety of poultry and seafood. The crude heparin sodium, after processing by downstream companies, is transformed into refined heparin sodium and heparin sodium injection solutions, which are major anticoagulants. Licorice preparations, such as compound licorice lozenges, are used as cough suppressants and supplied to retail pharmacies. For more information, visit the Company's website at: https://www.bgmgroupltd.com/ Forward-looking Statements This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. For investor and media inquiries, please contact: info@qiliancorp.com xinchen@qiliancorp.com View original content:https://www.prnewswire.com/news-releases/bgm-group-ltd-pioneers-innovation-in-ai-and-intel-technology-fostering-holistic-integration-of-healthcare-and-insurtech-302318792.html SOURCE BGM Group Ltd AIFUAIX Inc$1.478.09%WatchlistOverviewBGMBGM Group Ltd$8.0014.3%Market News and Data brought to you by Benzinga APIs

/C O R R E C T I O N -- BGM Group Ltd/ - AIX (NASDAQ:AIFU), BGM Group (NASDAQ:BGM)

In the news release, BGM Group Ltd. Pioneers Innovation in AI and Intel Technology, Fostering Holistic Integration of Healthcare and Insurtech, issued 29-Nov-2024 by BGM Group Ltd over PR Newswire, we are advised by the company that the headline should read "[BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech]" rather than "[BGM Group Ltd. Pioneers Innovation in AI and Intel Technology, Fostering Holistic Integration of Healthcare and Insurtech]" as originally issued inadvertently. The complete, corrected release follows: BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. BGM ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. AIFU ("AIX") valued at 1 billion RMB (approximately $140 million). The intelligent platform encompasses AIX's subsidiaries - RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"). Completion of the transaction is anticipated by the end of 2024. Through this strategic acquisition, BGM formally ventures into the domains of AI intelligent technology and financial and insurance services, setting the stage for diversified growth beyond biopharmaceuticals and inaugurating a new era for the Company in the digital and intelligent landscape. Mr. Xin Chen, CEO of BGM, commented, "AIX's efforts in digital innovation and intelligent transformation have yielded remarkable outcomes. Their accumulated technology and expertise will serve as a crucial reference for our own transformation in the pharmaceutical and healthcare sectors. This collaboration will not only bolster BGM's technological capabilities but also expedite our strategic development, enabling us to deliver more efficient and intelligent solutions to the global market. This partnership represents a mutually beneficial opportunity and I am optimistic about our future together." Mr. Hu Yinan, CEO of AIX, stated, "Intelligent technology is the future of the insurance sector. AIX's intelligent platform has already exhibited significant potential within the industry. However, broader advancement requires an open industry perspective and ecological support. Partnering with BGM will allow our platform to reach a wider user base and unlock greater potential for AI technology beyond the insurance realm. Furthermore, this collaboration aligns with national elderly care policies and promotes the growth of the silver economy. By extending our intelligent capabilities from insurance into the pharmaceutical and healthcare sectors, we aim to facilitate industry transformation through technology and propel AIX's growth. AIX will maintain its role as the primary user of the intelligent platform, actively investing resources to maximize its technological capabilities. We are confident that this collaboration will create new opportunities for both AIX and the intelligent platform, enhancing value for our customers, industry partners, and shareholders." Founded in 2009, RONS Technology, a wholly-owned subsidiary of AIX, specializes in developing digital and intelligent technologies for the financial and insurance industries. RONS Technology boasts extensive experience in insurtech, having introduced disruptive innovations through its RONS Open Platform and flagship product Du Xiaobao. RONS Technology has steadily built a strong presence within the insurtech landscape, offering substantial growth potential and development opportunities. Established in 2004, Xinbao Investment has developed a professional integrated online and offline insurance trading and service platform known as "Baowang". Baowang provides comprehensive risk protection solutions for individuals, families, and small to medium-sized enterprises through the integration of technology, products, and services. The platform currently offers over 300 flagship products from more than 30 insurance companies, addressing various protection needs such as critical illness, term life, accident, health, travel, and corporate insurance. By acquiring RONS Technology and Xinbao Investment, BGM will effectively integrate resources from intelligent technology and biopharmaceuticals, creating a new landscape for the synchronized development of "healthcare, medicine, and insurance" in the global market. The technological innovations from RONS Technology, particularly the pioneering achievements of Du Xiaobao in insurance sales, will empower BGM to strengthen its competitive advantage at the intersection of medical technology and insurance technology, offering users comprehensive and intelligent healthcare and insurance solutions while further expanding its global influence. Moreover, RONS Technology and Xinbao Investment will benefit from enhanced development opportunities arising from this transaction. BGM's robust presence in the healthcare sector, especially its extensive footprint in the global pharmaceutical market, will provide additional application scenarios for the products and services of both entities. RONS Technology and Xinbao Investment intend to leverage BGM's international market network and pharmaceutical expertise to explore novel development models within the healthcare and insurance industries, continuously broaden their market reach, and serve as potent profit generators for BGM in the future. About BGM Group Ltd BGM Group Ltd,headquartered in Chengdu, China, is an innovative company dedicated to the fields of biopharmaceuticals, bio-extraction, and medical health. Our current product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. The oxytetracycline API not only provides raw materials for pharmaceutical companies to produce human antibiotics but also supports the global breeding and livestock industries to ensure the safety of poultry and seafood. The crude heparin sodium, after processing by downstream companies, is transformed into refined heparin sodium and heparin sodium injection solutions, which are major anticoagulants. Licorice preparations, such as compound licorice lozenges, are used as cough suppressants and supplied to retail pharmacies. For more information, visit the Company's website at: https://www.bgmgroupltd.com/ Forward-looking Statements This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. For investor and media inquiries, please contact: info@qiliancorp.com xinchen@qiliancorp.com View original content:https://www.prnewswire.com/news-releases/bgm-group-ltd-pioneers-innovation-in-ai-and-intel-technology-fostering-holistic-integration-of-healthcare-and-insurtech-302318792.html SOURCE BGM Group Ltd Market News and Data brought to you by Benzinga APIs

AIX Inc. (NASDAQ:AIFU): Reshaping AI Insurance and the Healthcare Industry--A Promising Future Ahead? By Investing.com

, /PRNewswire/ -- AIX Inc. (NASDAQ:AIFU) is a leading company focused on insurance agency and claims services. Recently, the company has been gradually pushing for an intelligent and diversified transformation, aiming to capture growth opportunities in the AI insurance and healthcare sectors. The restructuring of its high-quality assets and a strategic partnership with BGM Group Ltd. (NASDAQ:BGM) are expected to create a second growth curve for the company's future performance. 1. Restructuring Quality Assets to Build a Smarter Future AIFU has recently undertaken the restructuring of its core assets, involving an amount of , including RONS Intelligent Technology (Beijing) Co., Ltd. ("RONS Technology") and Shenzhen Xinbao Investment Management Co., Ltd. ("Xinbao Investment"). This is not a simple "sale" transaction; the restructuring involves the Duxiaobao AI insurance platform, which provides intelligent solutions to the insurance market through AI and big data. AIFU exchanged these assets for 72% of BGM Group's shares, becoming the majority shareholder of BGM Group. This transaction is expected to significantly increase BGM Group's market value and open up new opportunities for AIX Inc.'s future development. Currently, BGM Group's market value has not yet been fully realized in the secondary market. If the AI insurance business expands rapidly, BGM Group's market value and stock price are likely to undergo significant revaluation. With a market value of approximately , AIFU stands in stark contrast to Prudential Insurance (PUK, market value of ) and Prudential Financial (PRU, market value of ). While Prudential focuses primarily on traditional insurance products, AIFU is poised to disrupt the industry with AI-driven solutions, supported by Baidu's big data, which will effectively reduce costs, expand market share, and improve customer satisfaction. 4. Pharmaceutical (TADAWUL:2070) and Healthcare Strategy Driving Valuation Growth AIFU not only focuses on the AI insurance business but also heavily invests in the pharmaceutical and healthcare sectors, seizing new opportunities brought about by global population aging. Key driving factors include: Through the strategic restructuring with BGM Group, AIFU has formed a powerful alliance in both the AI insurance and healthcare sectors, positioning itself to become an industry leader. Whether in terms of BGM Group's valuation potential or AIFU's business expansion, this transaction presents a unique opportunity for investors. The dual drivers of AI insurance and healthcare will be the cornerstone of the company's future development.